PGEN
Price
$1.76
Change
-$0.10 (-5.38%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
516.91M
57 days until earnings call
YMAB
Price
$4.87
Change
-$0.29 (-5.62%)
Updated
Mar 10, 03:27 PM (EDT)
Capitalization
233.33M
63 days until earnings call
Ad is loading...

PGEN vs YMAB

Header iconPGEN vs YMAB Comparison
Open Charts PGEN vs YMABBanner chart's image
Precigen
Price$1.76
Change-$0.10 (-5.38%)
Volume$11.93K
Capitalization516.91M
Y-mAbs Therapeutics
Price$4.87
Change-$0.29 (-5.62%)
Volume$513
Capitalization233.33M
PGEN vs YMAB Comparison Chart
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. YMAB commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Hold and YMAB is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (PGEN: $1.78 vs. YMAB: $4.96)
Brand notoriety: PGEN and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 62% vs. YMAB: 138%
Market capitalization -- PGEN: $516.91M vs. YMAB: $215.69M
PGEN [@Biotechnology] is valued at $516.91M. YMAB’s [@Biotechnology] market capitalization is $215.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both PGEN and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 4 bullish TA indicator(s).

  • PGEN’s TA Score: 4 bullish, 5 bearish.
  • YMAB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than PGEN.

Price Growth

PGEN (@Biotechnology) experienced а +2.89% price change this week, while YMAB (@Biotechnology) price change was -11.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.83%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.34%.

Reported Earning Dates

PGEN is expected to report earnings on May 07, 2025.

YMAB is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+0.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($517M) has a higher market cap than YMAB($233M). PGEN YTD gains are higher at: 58.929 vs. YMAB (-36.654). YMAB has higher annual earnings (EBITDA): -27.87M vs. PGEN (-136.11M). YMAB has more cash in the bank: 68.1M vs. PGEN (28.6M). YMAB has less debt than PGEN: YMAB (1.08M) vs PGEN (5.75M). YMAB has higher revenues than PGEN: YMAB (84.6M) vs PGEN (3.96M).
PGENYMABPGEN / YMAB
Capitalization517M233M222%
EBITDA-136.11M-27.87M488%
Gain YTD58.929-36.654-161%
P/E RatioN/AN/A-
Revenue3.96M84.6M5%
Total Cash28.6M68.1M42%
Total Debt5.75M1.08M535%
FUNDAMENTALS RATINGS
PGEN vs YMAB: Fundamental Ratings
PGEN
YMAB
OUTLOOK RATING
1..100
7570
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3693
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for PGEN (73) in the null industry. This means that YMAB’s stock grew somewhat faster than PGEN’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

YMAB's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (36) in the null industry is somewhat better than the same rating for YMAB (93) in the Pharmaceuticals Major industry. This means that PGEN’s stock grew somewhat faster than YMAB’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that PGEN’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENYMAB
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
89%
Bullish Trend 7 days ago
87%
Momentum
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
82%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
86%
Bearish Trend 7 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
85%
Bearish Trend 7 days ago
88%
Advances
ODDS (%)
Bullish Trend about 1 month ago
83%
Bullish Trend 25 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
86%
Bullish Trend 7 days ago
81%
Aroon
ODDS (%)
Bullish Trend 7 days ago
89%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with RCKT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+6.59%
RCKT - PGEN
44%
Loosely correlated
-1.48%
NKTX - PGEN
42%
Loosely correlated
+1.85%
ALEC - PGEN
42%
Loosely correlated
+3.19%
IDYA - PGEN
41%
Loosely correlated
-1.78%
ARWR - PGEN
41%
Loosely correlated
-3.39%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with FATE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-4.43%
FATE - YMAB
46%
Loosely correlated
-7.77%
RCKT - YMAB
45%
Loosely correlated
-1.48%
ARWR - YMAB
43%
Loosely correlated
-3.39%
NKTX - YMAB
43%
Loosely correlated
+1.85%
CRSP - YMAB
42%
Loosely correlated
+2.74%
More